Indeed, the study results presented here demonstrated that simultaneous inhibition of integrin αv, STAT3, and GSK3β using cilengitide, WP1066, and AR-A014418, respectively, synergizes with anti–PD-1 therapy and offers a complete tumor regression in about 50% of GBM tumor–bearing mice. Here, STAT3 is linked to neoplasm.